Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsAmeriHealth step therapy Prior Auth guidance | Ope…
    Ask Trek AI about this page
    CurrentAmeriHealthPolicy N/A

    Formulary step therapy and prior authorization rules for selected drugs

    Customize your policy alerts

    Sign up for all AmeriHealth policy alerts

    Know when AmeriHealth releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines utilization management restrictions (step therapy, prior authorization, quantity limits) for specific prescription drugs on the AmeriHealth Medicare PPO formulary; applies to prescribers and network pharmacies serving AmeriHealth Medicare PPO members.

    Policy Summary
    PayerAmeriHealth
    PolicyFormulary step therapy and prior authorization rules for selected drugs
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Last ReviewJan 20, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization when required and complete any required step therapy trials before dispensing.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    multipleFormulary products with ST/PA details

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ST required
    Step therapy examples
    PA referencedPA referenced
    index presentDrug index pages

    Drug-specific Coverage Criteria

    Fetzima (example)

    Covered when ALL of the following are met (examples from product listings):

    Fetzima (levomilnacipran) new start: Trial of two of the following generic formulary serotonin-norepinephrine reuptake inhibitors (SNRIs): desvenlafaxine tablet, duloxetine capsules, venlafaxine hydrochloride immediate release tablets, venlafaxine hydrochloride capsules.trial of 2 agents

    Applies to new starts

    Fanapt

    Covered when ALL of the following are met:

    Fanapt new start: Trial of two generic formulary antipsychotic products.trial of 2 agents

    Applies to new starts

    Drizalma

    Covered when ALL of the following are met:

    Drizalma new start: Trial of generic formulary duloxetine.trial of 1 agent

    Applies to new starts

    Exxua and related antidepressants

    Covered when ALL of the following are met:

    Exxua new start: Trial of two of the following: bupropion, citalopram tablets, desvenlafaxine extended-release (ER), duloxetine capsules, escitalopram tablets, fluoxetine, mirtazapine tablet, paroxetine IR/ER, sertraline tablets, venlafaxine IR/ER.trial of 2 agents

    Applies to new starts

    Basaglar (insulin) requirements

    Covered when ALL of the following are met:

    Basaglar: Trial of two of the following: Lantus, Toujeo, Tresiba.trial of 2 agents

    Always applies

    Rebif (multiple sclerosis)

    Covered when ALL of the following are met:

    Rebif new start: Trial of two of the following formulary products: Avonex (interferon beta-1a), Betaseron (interferon beta-1b), Glatopa (glatiramer acetate), Tecfidera (dimethyl fumarate), Gilenya (fingolimod), Teriflunomide.trial of 2 agents

    Applies to new starts

    Relistor

    Covered when ALL of the following are met:

    Relistor: Trial of lubiprostone or lactulose.trial of 1 agent

    Always applies

    Sancuso

    Covered when ALL of the following are met:

    Sancuso patch: Trial of (a) ondansetron or granisetron and (b) aprepitant.trial of 2 classes/agents

    Always applies

    Savella (milnacipran)

    Covered when ALL of the following are met:

    Savella: Trial of generic formulary duloxetine.trial of 1 agent

    Applies to new starts

    Xcopri

    Covered when ALL of the following are met:

    Xcopri new start: Trial of two generic formulary anticonvulsants.trial of 2 agents

    Applies to new starts

    Zonisade

    Covered when ALL of the following are met:

    Zonisade: Trial of generic zonisamide capsule.trial of 1 agent

    Applies to new starts

    Some covered drugs may have additional requirements or limits on coverage known as utilization management. These may include Prior Authorization (PA) — plan approval required before dispensing for certain products; Step Therapy (ST) — a requirement that specified alternative drugs be tried first for new starts; and Quantity Limits (QL) — limits on the amount of drug the plan will cover. Specific drugs subject to PA are listed in the 2026 Utilization Management Criteria: Prior Authorization, and drugs with QLs are listed in the AmeriHealth Medicare PPO Formulary (List of Covered Drugs). Providers and members should consult the Formulary or www.amerihealthmedicare.com for details and for the exception request process.

    Initial Therapy (New Starts)

    Initial therapy (new starts)

    Initial therapy (new starts) requires trials of specified formulary alternatives as listed per product.

    General new start rule: New starts must trial the specified generic formulary alternatives as listed for each product (see product-specific entries).as specified per product

    Applies to new starts

    Step Therapy Requirements

    ProductRequired trial(s) of formulary alternative(s)
    {"text":"Fetzima (levomilnacipran ER)","status":""}|{"text":"Trial of two of the following generic formulary SNRIs: desvenlafaxine tablet; duloxetine capsules; venlafaxine HCl immediate‑release tablets; venlafaxine HCl capsules. Applies to new starts.","status":""}
    {"text":"Fanapt (iloperidone)","status":""}|{"text":"Trial of two generic formulary antipsychotic products. Applies to new starts.","status":""}
    {"text":"Drizalma (drizalma sprinkle)","status":""}|{"text":"Trial of generic formulary duloxetine. Applies to new starts.","status":""}
    {"text":"Exxua (extended‑release antidepressant)","status":""}|{"text":"Trial of two of the following: bupropion; citalopram tablets; desvenlafaxine ER; duloxetine; escitalopram; fluoxetine; mirtazapine; paroxetine IR/ER; sertraline; venlafaxine IR/ER. Applies to new starts.","status":""}
    {"text":"Basaglar (insulin glargine) KwikPen","status":""}|{"text":"Trial of two of the following: Lantus; Toujeo; Tresiba. Always applies.","status":""}
    {"text":"Rebif (interferon beta‑1a)","status":""}|{"text":"Trial of two of the following formulary products: Avonex; Betaseron; Glatopa; Tecfidera (dimethyl fumarate); Gilenya (fingolimod); Teriflunomide. Applies to new starts.","status":""}
    {"text":"Relistor (methylnaltrexone)","status":""}|{"text":"Trial of lubiprostone or lactulose. Always applies.","status":""}
    {"text":"Sancuso (granisetron/ondansetron patch)","status":""}|{"text":"Trial of (a) ondansetron or granisetron and (b) aprepitant. Always applies.","status":""}
    {"text":"Savella (milnacipran)","status":""}|{"text":"Trial of generic formulary duloxetine. Applies to new starts.","status":""}
    {"text":"Xcopri (cenobamate)","status":""}|{"text":"Trial of two generic formulary anticonvulsants. Applies to new starts.","status":""}
    {"text":"Zonisade (zonisamide suspension)","status":""}|{"text":"Trial of generic zonisamide capsule. Applies to new starts.","status":""}

    Provider Actions and Requirements

    Prior Authorization

    Prior Authorization Required

    Our plan requires prior authorization (PA) for certain drugs listed in the 2026 Utilization Management Criteria: Prior Authorization. Failure to obtain required PA may result in denial of coverage and the claim being the member's financial responsibility.

    • Drugs requiring PA are identified in the plan Utilization Management Criteria and the Formulary 'Requirements' column.
    • If PA is not obtained before dispensing, the plan may deny coverage for the drug.
    • Providers may request an exception or submit an appeal if initial PA is denied.
    Step Therapy

    Step Therapy Requirements

    Step therapy (ST) applies to certain covered drugs. For new starts, members must generally try specified formulary alternatives (step agents) and meet the listed trial criteria before the plan will cover the requested non-preferred product.

    • Step therapy requirements and the specific alternative drugs (e.g., trials of two generic formulary SNRIs for Fetzima, two generic formulary antipsychotics for Fanapt) are listed under each affected product in this document.

    Key Definitions

    Step Therapy — definition (ST)
    DefinitionStep Therapy (ST): requirement to try specified drugs first before coverage of another drug; drugs that require step therapy are listed in this document.
    ApplicabilityApplies when a drug in the AmeriHealth Medicare PPO Formulary has the note 'ST' in the 'Requirements' column; see the index and the product-specific entries in this document for required trials.
    Typical requirementNew starts generally must trial the specified generic formulary alternatives (examples: trial of two agents for many products; one agent for some).
    Related resourcesSee the AmeriHealth Medicare PPO Formulary (List of Covered Drugs) and the index on page 15 for locating affected drugs and their step therapy details.
    Exception processMembers or providers may request an exception to step therapy restrictions; details are in the Formulary and Evidence of Coverage.

    Background and Scope

    This document summarizes the utilization management requirements that apply to selected drugs on the AmeriHealth Medicare PPO plan, including step therapy, prior authorization, and quantity limits. It is intended to be used together with the 2026 Utilization Management Criteria and the plan Formulary; those sources contain full details on which drugs require PA, the specific alternative therapies required by ST, quantity limits, and the process for exceptions or questions. The guidance here identifies products affected and the trials or requirements that typically apply for new starts.

    Policy Summary
    PayerAmeriHealth
    PolicyFormulary step therapy and prior authorization rules for selected drugs
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Last ReviewJan 20, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization when required and complete any required step therapy trials before dispensing.
    SourceLink
    On This Page
    Drug-specific Coverage CriteriaInitial Therapy (New Starts)Step Therapy RequirementsProvider Actions and RequirementsKey DefinitionsBackground and Scope
  1. Step therapy 'Applies to new starts' means existing stable therapy may be excluded from ST requirements; review product details for exceptions.
  2. Providers may request an exception if the required step agents are not appropriate for the member.
  3. Documentation Required

    Documentation and Contact

    Providers must follow the plan's PA and step therapy procedures and include supporting clinical documentation when submitting requests. For assistance or to check specific drug requirements, contact the Member Help Team.

    • Include relevant clinical notes, prior medication history, and rationale for exceptions when requesting PA or step therapy exceptions.
    • Use the Formulary and the 2026 Utilization Management Criteria to identify required documentation and trial details.
    • For questions or to initiate PA/exception requests, call 1-866-569-5190 (TTY 711) or visit www.amerihealthmedicare.com.
    Denial Risk

    Prior Authorization Denial Risk

    If required prior authorization or step therapy requirements are not met, the plan may deny coverage and the member may be responsible for the cost. Providers should confirm authorization status prior to dispensing.

    • Denial risk applies when PA is not obtained or step therapy trials are not documented as required.
    • Timely submission of complete documentation can reduce denials; follow up on PA decisions promptly.
    • Members and providers may request exceptions or appeals per plan procedures if coverage is denied.
    Prior Authorization — definition (PA)
    DefinitionPrior Authorization (PA): approval required from the plan before the prescription will be covered; certain drugs require PA as listed in the 2026 Utilization Management Criteria: Prior Authorization.
    Consequence of no PAIf you do not obtain required prior authorization, the plan may not cover the drug.
    How to determine if PA appliesDrugs that require prior authorization are listed in the 2026 Utilization Management Criteria: Prior Authorization and noted in the Formulary requirements column.
    How to request PA or helpFollow the processes described in the Formulary and 2026 Utilization Management Criteria; contact AmeriHealth Medicare PPO Member Help Team for assistance (1-866-569-5190; TTY 711).